Invivyd Reports Positive Phase 3 LIBERTY Results for VYD2311 and Plans Accelerated Approval Submission

Invivyd reported statistically significant Phase 3 safety and tolerability results for VYD2311 compared with an mRNA-based COVID-19 vaccine and said it plans to pursue an Accelerated Approval BLA pending supportive results from its ongoing DECLARATION study. Key Investor TakeawaysInvivyd (NASDAQ:IVVD) said VYD2311 showed significantly lower rates of short-term overall adverse events and systemic adverse events than the mRNA COVID-19 vaccine in the Phase 3 LIBERTY study.